| 2006 | A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma | 성주명 | Article |
| 2023 | A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients with Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone | 문영철 | Article |
| 2010 | Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: Results of the Korean Multiple Myeloma Working Party (KMMWP) | 성주명 | Article |
| 2014 | Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: A prospective multicenter study | 문영철 | Article |
| 2014 | Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: Web-based multicenter registry study | 문영철 | Article |
| 2012 | Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL) | 문영철 | Article |
| 2009 | Clinical features and survival outcomes in patients with multiple myeloma: Analysis of web-based data from the korean myeloma registry | 문영철 | Article |
| 2011 | Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: Surgical resection followed by chemotherapy versus chemotherapy alone | 문영철 | Article |
| 2017 | Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy | 문영철 | Article |
| 2013 | Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation | 문영철 | Article |
| 2011 | Immunoglobulin D multiple myeloma: Response to therapy, survival, and prognostic factors in 75 patients | 문영철 | Article |
| 2017 | Improved prognostic stratification using NCCN- and GELTAMOinternational prognostic index in patients with diffuse large B-cell lymphoma | 문영철 | Article |
| 2014 | Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea - Experience from 110 patients | 문영철 | Article |
| 2013 | Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT | 문영철 | Article |
| 2011 | Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL) | 문영철 | Article |
| 2003 | Outcome of adult severe or very severe aplastic anemia treated with immunosuppressive therapy compared with bone marrow transplantation: Multicenter trial | 성주명 | Article |
| 2012 | Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL) | 문영철 | Article |
| 2018 | Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma | 문영철 | Article |
| 2012 | Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: Results of a phase II trial | 성주명 | Article |
| 2017 | The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: A retrospective multicenter study (KMM160) | 문영철 | Article |
| 2015 | Treatment outcomes of rituximab plus hyper-CVAD in korean patients with sporadic burkitt or burkitt-like lymphoma: Results of a multicenter analysis | 문영철 | Article |
| 2012 | VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large b cell lymphoma | 정화순; 문영철 | Article |
| 2015 | Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL) | 문영철 | Article |
